Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Type 1 diabetes for ≥ 5 years~2. On their current insulin regimen for ≥ 3 months prior to study entry~3. Screening HbA1c result ≤ 7.5% (58 mmol/mol)~4. Reports self testing of blood glucose levels on a regular basis equivalent to a minimum of 3 times daily for at least 2 months prior to study entry~5. In the investigator's opinion the subject is considered technically capable of using the Abbott Sensor Based Glucose Monitoring System~6. Aged 18 years or over.~Exclusion Criteria:~1. Subject has been diagnosed with hypoglycaemic unawareness (i.e. subject has a diagnosis of impaired awareness of hypoglycaemia recorded in their medical notes OR in the investigator's opinion the subject currently experiences less than minimal warning symptoms for impending hypoglycaemia)~2. Subject is currently prescribed animal insulin~3. Subject is currently prescribed oral steroid therapy or is likely to require oral steroid therapy for any acute or chronic condition during the study~4. Has known allergy to medical grade adhesives~5. Currently participating in another device or drug study that could affect glucose measurements or glucose management~6. Currently using a Continuous Glucose Monitoring (CGM) device or has used one within the previous 4 months~7. Currently using Sensor augmented pump therapy~8. Is planning to use a CGM device at any time during the study~9. A female subject who is pregnant or planning to become pregnant within the study duration~10. A breast feeding mother~11. Currently receiving dialysis treatment or planning to receive dialysis during the study~12. Has a pacemaker~13. Has experienced an acute myocardial infarction within previous 6 months~14. Has a concomitant disease or condition that may compromise subject safety including; unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical condition~15. Has experienced an episode of confirmed or suspected diabetic ketoacidosis (DKA) in the previous 6 months~16. In the investigator's opinion, the subject is considered unsuitable for inclusion in the study for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensor Based Glucose Monitoring System (Type: EXPERIMENTAL): Standard sensing system use for 6 months.
- Standard Blood Glucose Monitoring (Type: ACTIVE_COMPARATOR): Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).